---

Highlights of April 2021

1. RDIF and Panacea Biotec agree to produce 100 million doses of Sputnik V Corona vaccine in India per year.
2. Merck inks licensing pact with Cipla, Sun Pharma, Dr Reddy’s Laboratories, Emcure Pharmaceuticals and Hetero Labs for oral COVID drug Molnupiravir.
3. Sun Pharma acquires stake in Pharmarack Technologies.
4. CSIR-IICT ink agreement with Bharat Biotech for novel vaccines platforms.
5. Cidara inks up to US$780 Million deal for antiviral conjugates.
6. Vertex taps Obsidian in controllable genetic medicines deal that could reach US$75 Million upfront.
7. Fortress Biotech partner gets rights to Lilly’s Qbrexza.
8. Sterling Pharma Solutions confirms acquisition of ADC Bio.
9. Gilead Sciences and Novo Nordisk have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH).
10. Pfizer buys Amplyx to grow infectious disease pipeline.

Highlights at Aagami: 

1. A US based company making Novel Portable Point-Of-Care MRI for Neuro Imagingand Interventions, appointed Aagami to support its fund raising and business development initiatives.
2. 2 Existing clients extended their contracts with Aagami, resulting from the professional support and encouraging results.
3. Aagami to attend BIO Digital International, Bio Pharm America and Bio-Europepartnering conferences.